The day’s top news stories from stocks on the GuerillaStockTrading watch list.
Continue reading “Top News Stories November 28 2017”
Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.
While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.
We have been stalking Abbott Laboratories for an entry. With FDA clearance of its Alinity mobile blood test unit and recent pullback, now may be the time for an entry.